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Abstract 
Background: Coronavirus disease 2019 (COVID-19) is a concern in the medical community as the virus spreads 
around the world. It has a heavy global burden, particularly in low-income countries. This virus has its specific 
outcomes in each population. Hence, it is necessary to design studies to find the epidemiological behaviour of 
this virus. 
Materials and Methods: This cross-sectional study was conducted in the Labbafinezhad hospital, Tehran, Iran. 
Demographic features include age, sex, past medical history, drug history, habitual file, influenza vaccination 
history, recent exposure history, clinical symptoms or signs, and the recorded symptoms. The clinical 
examination and para-clinical assessment, including chest computed tomography (CT) and laboratory testing on 
admission, were recorded. 
Results: It was found that patients with a history of kidney transplantation, high level of LDH, high level of 
AST, and increased neutrophil to lymphocyte ratio are most at risk of death. 
Conclusion: Parameters mentioned could help practitioners predict patient outcomes, and necessary interventions 
could be considered in this regard. 
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Introduction 
Coronavirus disease 2019 (COVID-19) is a family of 
large enveloped non-segmented positive-sense RNA 
viruses in the same subgenus with severe acute 
respiratory syndrome CoV (SARS-CoV) but a 
different clade. It was first reported in December 2019 
in Wuhan, China, with a cluster of unexplained 
pneumonia that soon turned into a global pandemic1. 
The CoVs have become the significant pathogens of 
emerging respiratory disease outbreaks. According to 
the World Health Organization (WHO) website, as of 
June 29, 2020, COVID-19 has caused 10 021 401 
confirmed cases and 499 913 confirmed deaths2. 
In Iran, it was first reported in Qom province on 
February 19, 2020, which soon rapidly spread over all 
the provinces of the country3. As of June 29, 2020, a 
total of 225 205 confirmed cases and 10 670 confirmed 
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death had been documented in Iran. Of note, in recent 
weeks, the second wave of the infection has been 
encountered in Iran as a rapid surge in the numbers of 
COVID-19 cases, and the mortality rate has been 
evident. 
The COVID-19 could affect all the age groups. 
Despite the initial impression that children are 
immune, many disease cases are reported at a younger 
age4, 5. Following an incubation period of 2-14 days, 
non-specific symptoms such as malaise, fever, and dry 
cough will appear. Depending on the patient’s 
immunity system level and concurrent comorbidities, 
the symptoms might remain mild or lead to severe 
pneumonia, acute respiratory distress syndrome, and 
eventually multiple organ damage and even death6-8. 
Although the main symptoms are confined to the 
respiratory system, non-respiratory complications 
such as the intestinal tract, renal, hepatic, 
cardiovascular system, central and peripheral nervous 
system, and lymphocytopenia have been reported8, 9. 
Additionally, the main para-clinical features include 
leukocytosis, lymphopenia, elevated C-reactive 
protein (CRP), and evidence of ground-glass opacity 
on chest computed tomography (CT)10. 
In clinical management, several investigational 
therapeutics such as hydroxychloroquine, 
azithromycin, ribavirin, interferon, lopinavir-ritonavir 
remdesivir, favipiravir, and corticosteroids have been 
used. However, the efficacy of these drugs remains 
controversial11-13. Given the increasing pattern of 
COVID-19 and lack of epidemiological study on 
COVID-19 in Iran, herein, we aimed to investigate the 
clinical, para-clinical features and medical approaches 
in a selected group of patients in Labbafinezhad 
Hospital to contribute to a better understanding of the 
nature of the disease. 
Methods 
Study design: This cross-sectional study was 
conducted from March 01, 2020, to April 30, 2020, in 
the Labbafinezhad hospital, Tehran, Iran. The study 
was approved by the local ethics committee (Code: 
IR.SBMU.RETECH.REC.1399.100). Besides, 
written informed consent was obtained from all 
patients before they participated in this study.  
Study population: This is a newly emerging 
pandemic pertained to COVID-19. We had to enroll 
all the patients with COVID-19 referred to our center 
who fulfilled the inclusion criteria consisting of patients 
with laboratory-confirmed COVID-19 who were 
hospitalized in our center according to our national 
treatment protocol. 
COVID-19 was diagnosed based on the WHO interim 
guidance14. A confirmed case of COVID-19 was 
defined as a positive result on the real-time reverse-
transcriptase–polymerase-chain-reaction (RT-PCR) 
assay of nasopharyngeal swab specimens. 
Data gathering: Following the hospitalization of 
patients, the data collection was performed by a 
checklist consisting of demographic features like age, 
sex, past medical history, drug history, habitual file, 
influenza vaccination history, recent exposure history, 
clinical symptoms or signs, and the duration of the 
symptoms. The clinical examination and para-clinical 
assessment, including chest computed tomography 
(CT) and laboratory testing on admission, were 
recorded.  
Laboratory assessments consisted of a complete blood 
count, blood chemical analysis, coagulation testing, 
liver and renal function assessment, and measures of 
electrolytes, C-reactive protein, vitamin D, troponin, 
and creatine kinase. Clinical examination included a 
vital sign and systemic examination. (We defined the 
severity of the disease based on the guideline on 
COVID-19 issued by the Iranian National Health 
Commission.) 
Consequently, the patients underwent medical 
treatment according to the national treatment protocol. 
The chest CT was repeated on the fifth day of 
hospitalization. 
We eventually retrieved the patients' clinical profile, 
including medication regimen with the type, dosage, 
and duration of the therapy, the systemic examination 
on the second and fifth day of hospitalization, duration 
of the hospitalization, the prognosis of the disease, and 
the mortality rate. 
Statistical analysis: After data collection, the 
statistical analysis was performed using SPSS software 
version 22.0. For descriptive analysis, continuous 
variables were presented as medians and compared by 
the Mann-Whitney U test. Categorical variables are 
presented as numbers and percentages and were 
compared by chi-square or Fisher exact test. A two-
side P-value 0<0.05 was considered statistically 
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significant. 
Results 
This study evaluated the records of 230 patients 
diagnosed with SARS-CoV-2 infection, and some 
necessary variables were extracted. The demographic 
information, clinical characteristics, laboratory 
results, therapeutic interventions, and outcomes of 
patients were extracted. The median age of patients 
was 58 years old (interquartile 48-72 years). 137 
(59.6%) of patients were also male. Hypertension 
(39.1%), diabetes mellitus (32.6%), and 
cardiovascular diseases (22.7%) were the most 
common underlying diseases among the patients. 134 
(58.26%) of patients had at least one underlying 
disease. 19 (8.3%) patients also had a history of 
kidney transplantation and were taking 
immunosuppressive agents. Angiotensin-converting 
enzyme inhibitors also were used by 14 (6.1%) of 
patients. These results are also categorized according 
to the final clinical outcome and are presented 
in Table 1.  
As seen in Table 1, those elder patients (P= 0.040) 
with diabetes (P=0.019), hypertension (P=0.027), and 
lung diseases (P=0.037) had significantly more 
mortality. 
The results of initial clinical symptoms at the 
admission time showed that Dyspnea (66.1%), cough 
(55.7%), and myalgia (34.3%) were the most frequent 
symptoms. Headache (5.7%) and sore throat (0.4%) 
were seen with less frequency. These results are also 
categorized according to the final clinical outcome and 
are presented in Table 2. As seen in Table 2, there were 
no statistical differences between surviving and non-
survive groups in terms of initial clinical symptoms (all 
P values > 0.05). 
The laboratory results of patients are also summarized 
in Table 3. Laboratory parameters including LDH, 
Creatinine, AST, ALT, and neutrophil to lymphocyte 
ratio were statistically different between surviving and 
non-survived groups.  
The results of hospitalization also showed that the 
median time of hospitalization in survived patients was 
7 (5-11) days and in on-survived patients was 9 (5-14) 
days (P= 0.129). 
Using linear regression and stepwise approach, all 
variables were entered to find a model to predict 
mortality. It was found that patients with a history of 
kidney transplantation, high level of LDH, high level of 
AST, and increased neutrophil to lymphocyte ratio are 
primarily at risk of death. The summary of the proposed 




Table 1: The demographic characteristic of patients in this study. 
Variables Survived (n= 50) Non-survived (n= 180) P value 
Age (years) 58 (47-71) 62 (53-77) 0.040 
Male 99 (43.0 %) 36 (15.7) 0.177 
Diabetic 52 (22.60 %) 23 (10 %) 0.019 
Hypertension 64 (27.8 %) 26 (11.3 %) 0.027 
Lung diseases 13 (5.7 %) 0 (0.0 %) 0.037 
Chronic kidney diseases 21 (9.1 %) 10 (4.3 %) 0.101 
Cardio vascular diseases 37 (16.2 %) 15 (6.6 %) 0.116 
Kidney transplanted 12 (5.2 %) 7 (3.0 %) 0.089 
Angiotensin converting enzyme inhibitors usages 8 (3.5%) 5 (2.2 %) 0.284 
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Discussion 
This study aimed to find a clinical-epidemiological 
model for predicting the mortality among the SARS-
CoV-2 infection. In this regard, the medical records of 
230 patients were evaluated retrospectively. Clinical 
and para-clinical data were gathered, and the results 
showed that AST level, LDH level, neutrophil to 
lymphocyte ratio, and kidney transplantation are 
predictor indicators for mortality. 
The severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was first identified in patients with 
severe pneumonia in Wuhan, China, in late 2019. The 
clinical presentions of this disease are different 
according to the stage of the disease, which could affect 
the prognosis. Also, the laboratory and imaging 
findings and an underlying condition have their 
particular prognostic value . 
The dominant clinical features of COVID-19 were 
fever, cough, Dyspnea, and myalgia, while other 
symptoms were rare. Dyspnea was an acute clinical 
symptom that can determine clinical outcomes. Patients 
with Dyspnea at the time of admission had a poor 
clinical outcome compared to those with upper 
respiratory tract symptoms. 
Different studies investigated the underlying diseases in 
Table 2: The initial symptoms of patients in this study. 
Symptoms Survived (n= 50) Non-survived (n= 180) P value 
Fever 94 (40.9%) 27 (11.7%) 0.476 
Sore throat 1 (0.4%) 0 (0.0%) 0.783 
Myalgia 64 (27.8%) 15 (6.5%) 0.289 
Cough 99 (43.0%) 29 (12.6%) 0416 
Dyspnea 114 (49.6%) 38 (16.5%) 0.064 
Headache 10 (4.4%) 3 (1.3%) 0.572 
Gastrointestinal symptoms 23 (10.1%) 6 (2.6%) 0.560 
 
 
Table 3: The laboratory results of patients in this study. 
Variables 
Median (IQR) 
Survived (n= 50) Non-survived (n= 180) P value 
WBC 6.10 (4.70-8.30) 7.10 (4.90-10.00) 0.177 
Hb 13.30 (12.10-14.60) 12.90 (11.80-14.32) 0.282 
PLT 190.00 (153.00-235.00) 195.50 (135.00-264.00) 0.908 
CRP 40.00 (27.00-50.00) 40.00 (31.00-57.00) 0.217 
LDH 441.00 (341.00-556.00) 794.00 (590.00-1253.00) < 0.001 
Cr 1.17 (1.00-1.40) 1.51 (1.10-2.71) <0.001 
AST 30.00 (23.00-45.00) 50.00 (31.00-80.00) <0.001 
ALT 24.00 (16.00-42.00) 32.00 (19.00-59.00) 0.040 
N-L ratio 3.24 (1.86-5.30) 4.78 (3.31-8.80) <0.001 
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patients with COVID-19. Patients with at least one 
comorbidity, or even more, were associated with poor 
prognoses. This result is different from reported 
results in the MERS and SARS. The risk between 
cardiac diseases and poor clinical outcomes of 
influenza, SARS, or MERS infections was 
inconclusive . 
The most frequently reported laboratory abnormalities 
were lymphopenia and elevated CRP compatible with 
previous reports of patients with COVID-19. 
However, all these laboratory indicators are non-
specific, which makes their clinical application 
limited. In the Evaluation of suspected cases, 
physicians cannot rely on these laboratory 
abnormalities to exclude or confirm the diagnosis of 
COVID-19. 
Conclusion 
Above mentioned parameters could help the 
practitioners predict patient outcomes, and necessary 
interventions could be considered. 
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